×
About 1,348 results

ALLMedicine™ Oropharyngeal Cancer Center

Research & Reviews  655 results

Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV ass...
https://doi.org/10.1016/j.ijrobp.2021.04.015
International Journal of Radiation Oncology, Biology, Phy... Rischin D, King M et. al.

Jun 7th, 2021 - The excellent prognosis of patients with low risk HPV associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiotherapy and cisplatin, leading to interest in de-intensification trials...

Impact of smoking on stage-specific survival in human papilloma virus-associated oropha...
https://doi.org/10.1002/hed.26745
Head & Neck; Horwich P, Gundale A et. al.

May 18th, 2021 - The American Joint Committee on Cancer (AJCC) released a new staging system for human papilloma virus (HPV) positive oropharyngeal cancer (OPC) in their eighth edition. The role of smoking in HPV positive oropharyngeal cancer remains controversial...

Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-...
https://doi.org/10.1001/jamaoto.2021.0698
JAMA Otolaryngology-- Head & Neck Surgery; Aggarwal P, Hutcheson KA et. al.

May 6th, 2021 - Voice and speech production are critical physiological functions that affect quality of life and may deteriorate substantially after oropharyngeal cancer (OPC) treatment. There is limited knowledge about risk factors associated with voice and spee...

Investigating the association between serum human papillomavirus type 16 E7 antibodies ...
https://doi.org/10.1002/cam4.3944
Cancer Medicine; Huang CC, Su YC et. al.

May 5th, 2021 - Human papillomavirus (HPV) is recognized as a major cause of oropharyngeal cancer (OPC) in Western countries. Less is known regarding its contribution to the OPC occurring in Asia. The current study aimed to investigate the association between ant...

see more →

Clinicaltrials.gov  677 results

Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV ass...
https://doi.org/10.1016/j.ijrobp.2021.04.015
International Journal of Radiation Oncology, Biology, Phy... Rischin D, King M et. al.

Jun 7th, 2021 - The excellent prognosis of patients with low risk HPV associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiotherapy and cisplatin, leading to interest in de-intensification trials...

Impact of smoking on stage-specific survival in human papilloma virus-associated oropha...
https://doi.org/10.1002/hed.26745
Head & Neck; Horwich P, Gundale A et. al.

May 18th, 2021 - The American Joint Committee on Cancer (AJCC) released a new staging system for human papilloma virus (HPV) positive oropharyngeal cancer (OPC) in their eighth edition. The role of smoking in HPV positive oropharyngeal cancer remains controversial...

Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-...
https://doi.org/10.1001/jamaoto.2021.0698
JAMA Otolaryngology-- Head & Neck Surgery; Aggarwal P, Hutcheson KA et. al.

May 6th, 2021 - Voice and speech production are critical physiological functions that affect quality of life and may deteriorate substantially after oropharyngeal cancer (OPC) treatment. There is limited knowledge about risk factors associated with voice and spee...

Investigating the association between serum human papillomavirus type 16 E7 antibodies ...
https://doi.org/10.1002/cam4.3944
Cancer Medicine; Huang CC, Su YC et. al.

May 5th, 2021 - Human papillomavirus (HPV) is recognized as a major cause of oropharyngeal cancer (OPC) in Western countries. Less is known regarding its contribution to the OPC occurring in Asia. The current study aimed to investigate the association between ant...

see more →

News  15 results

ASCO: Deintensified treatment in p16+ oropharyngeal cancer needs evaluation
https://www.mdedge.com/hematology-oncology/article/200108/head-neck-cancers/asco-deintensified-treatment-p16-oropharyngeal?channel=39313
Caleb Rans

May 2nd, 2019 - Treatment deintensification for patients with p16+ oropharyngeal cancer (OPC) should occur only in the context of a clinical trial, according to a provisional clinical opinion released by the American Society of Clinical Oncology (ASCO). “The hypo.

HPV16 Vaccine Yields Added Benefit in Recurrent Throat Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/75474

Oct 3rd, 2018 - NEW YORK CITY -- Adding a tumor-specific vaccine to PD-1 checkpoint inhibition was safe and effective in HPV16-positive patients with recurrent or metastatic oropharyngeal cancer, a small phase II trial found. Among 24 patients treated with nivolu...

Risk for HPV-Related Throat Cancer Is 'Reassuringly' Low
https://www.staging.medscape.com/viewarticle/887728

Oct 26th, 2017 - The risk of developing oropharyngeal cancer (OPC) related to oral human papillomavirus (HPV) infection is very low in the general population and even in people with specific behavioral risk factors, a new study suggests. "Oropharyngeal cancer has ...

Risk for HPV-Related Throat Cancer Is 'Reassuringly' Low
https://www.medscape.com/viewarticle/887728

Oct 26th, 2017 - The risk of developing oropharyngeal cancer (OPC) related to oral human papillomavirus (HPV) infection is very low in the general population and even in people with specific behavioral risk factors, a new study suggests. "Oropharyngeal cancer has ...

Oral Sex, Smoking Increase Men's HPV Risk
https://www.medpagetoday.com/infectiousdisease/stds/68723

Oct 23rd, 2017 - Action Points Men who smoked and had five or more lifetime oral sex partners had the highest prevalence of oral oncogenic human papilloma virus (HPV) infection (14.9%). The study suggests that even though the prevalence of infection is higher in m...

see more →

Patient Education  1 results see all →